Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides

Area of Science:

• Neuroscience
• Biotechnology
• Nanomedicine

Background:

• The blood-brain barrier (BBB) restricts drug delivery to the central nervous system (CNS), hindering treatments for neurological disorders.
• Effective CNS drug delivery requires strategies to overcome the BBB's impermeability.

Purpose of the Study:

• To identify and develop novel peptide-based targeting agents for enhanced brain-specific drug delivery.
• To conjugate the identified peptide onto nanoparticles for improved CNS therapeutic efficacy.

Main Methods:

• Utilized a 12-mer phage display peptide library for in vivo screening to isolate brain-targeting peptides.
• Selected and synthesized a 12-amino-acid peptide, Pep TGN, for conjugation onto poly(ethyleneglycol)-poly(lactic-co-glycolic acid) (PEG-PLGA) nanoparticles (NPs).
• Evaluated cellular uptake, biodistribution, and brain targeting efficiency of Pep TGN-conjugated NPs in vitro and in vivo using fluorescent probes.

Main Results:

• Pep TGN demonstrated significant brain selectivity, with Pep TGN-conjugated NPs showing enhanced cellular uptake in bEnd.3 cells.
• In vivo studies revealed increased brain accumulation and reduced liver/spleen uptake of Pep TGN-conjugated NPs compared to plain NPs.
• The Drug Targeting Index (DTI) in the brain was significantly higher for targeted nanoparticles, confirming effective BBB penetration.

Conclusions:

• Pep TGN is a novel peptide motif with potent brain-targeting capabilities.
• Pep TGN-modified nanoparticles represent a promising platform for targeted drug delivery across the blood-brain barrier.
• This approach holds significant potential for advancing the treatment of central nervous system diseases.